Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) major shareholder Mpm Oncology Impact Management bought 81,500 shares of Sunesis Pharmaceuticals stock in a transaction on Monday, November 6th. The stock was purchased at an average price of $2.77 per share, with a total value of $225,755.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Mpm Oncology Impact Management also recently made the following trade(s):

  • On Thursday, November 2nd, Mpm Oncology Impact Management bought 25,300 shares of Sunesis Pharmaceuticals stock. The stock was purchased at an average price of $2.59 per share, with a total value of $65,527.00.

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) traded down $0.09 on Monday, hitting $2.91. 103,410 shares of the stock traded hands, compared to its average volume of 280,826. Sunesis Pharmaceuticals, Inc. has a 12-month low of $1.82 and a 12-month high of $4.45.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.06). During the same quarter in the previous year, the business posted ($0.62) EPS. sell-side analysts forecast that Sunesis Pharmaceuticals, Inc. will post -1.66 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/insider-buying-sunesis-pharmaceuticals-inc-snss-major-shareholder-buys-81500-shares-of-stock/1684020.html.

SNSS has been the topic of several recent analyst reports. Zacks Investment Research upgraded shares of Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a report on Thursday, August 24th. Cowen and Company restated a “hold” rating on shares of Sunesis Pharmaceuticals in a report on Thursday. Cantor Fitzgerald restated a “hold” rating and set a $3.00 price objective on shares of Sunesis Pharmaceuticals in a report on Wednesday, September 27th. Finally, ValuEngine downgraded shares of Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.

Several institutional investors and hedge funds have recently bought and sold shares of SNSS. Balyasny Asset Management LLC acquired a new position in shares of Sunesis Pharmaceuticals during the second quarter valued at about $5,400,000. Virtu KCG Holdings LLC acquired a new position in shares of Sunesis Pharmaceuticals during the second quarter valued at about $208,000. Sphera Funds Management LTD. boosted its position in Sunesis Pharmaceuticals by 54.6% in the second quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock valued at $522,000 after buying an additional 68,212 shares during the last quarter. Vanguard Group Inc. boosted its position in Sunesis Pharmaceuticals by 4.1% in the second quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after buying an additional 23,819 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in Sunesis Pharmaceuticals by 77.4% in the second quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 18,254 shares during the last quarter. Hedge funds and other institutional investors own 56.43% of the company’s stock.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.